Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.

Taşkın S., Gungor M. , Ortac F., Öztuna D.

Archives of gynecology and obstetrics, vol.288, pp.1399-403, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 288
  • Publication Date: 2013
  • Doi Number: 10.1007/s00404-013-2924-7
  • Title of Journal : Archives of gynecology and obstetrics
  • Page Numbers: pp.1399-403

Abstract

To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance